In recent years, bariatric surgery, also referred to as metabolic surgery, has become the most successful treatment option in those with Type 2 diabetes and obesity. There are some similarities in the pathological pathways in Type 1 and Type 2 diabetes, but the use of surgery in Type 1 diabetes remains unestablished and controversial. The treatment and management of Type 1 diabetes can be very challenging but recent advances in surgical interventions and technology has the potential to expand and optimize treatment options. This review discusses the current status of some surgical options available to people with Type 1 diabetes. These include implantable continuous glucose monitoring systems, continuous intraperitoneal insulin infusion pumps, closed-loop insulin delivery systems (also known as the artificial pancreas system) utilizing the latter two modalities of glucose monitoring and insulin delivery, and bariatric or metabolic surgery. Whole pancreas and islet transplantation are beyond the scope of this review but are briefly discussed.
Introduction
The ultimate goals of diabetes management include optimization of glycaemic control, minimizing hypoglycaemia risk, prevention of diabetes-related complications and preserving quality of life. In recent years, a significant amount of focus and attention has been drawn towards the anti-diabetes effect of metabolic surgery in people with Type 2 diabetes and obesity. The beneficial effects include long-term resolution of Type 2 diabetes and improvement of its associated comorbidities. As a result, surgical intervention has been incorporated into many international Type 2 diabetes treatment guidelines (1) .
Type 1 diabetes is classically defined as a disease of insulin deficiency as opposed to insulin insufficiency or resistance in Type 2 diabetes. The onset tends to be much earlier in life, typically in childhood or adolescence. Its precise mechanism is not entirely known but is thought to include both genetic and autoimmune factors. People with Type 1 diabetes rely on exogenous insulin replacement therapy for survival (2) .
Diagnosis and differentiation between Type 1 and Type 2 diabetes can sometimes be challenging and the prevalence of Type 2 diabetes far outnumbers that of Type 1 diabetes. However, morbidity and mortality associated with Type 1 diabetes still remains high, and management of the condition can be challenging for healthcare professionals and for individuals with Type 1 diabetes. This review will explore and evaluate some of the potential surgical options for glycaemic control in those with Type 1 diabetes, including implantable continuous glucose sensors, continuous intraperitoneal infusion pumps, automated insulin delivery systems and metabolic surgery. As the role of surgery in Type 2 diabetes for those with and without obesity is established, the next logical question is whether these benefits can be extended to those with Type 1 diabetes? Do surgery and surgeons have a role in the management of Type 1 diabetes, particularly for those who are also obese? A detailed review of whole pancreas and islet transplantation is beyond the scope of this review but they are discussed briefly.
Implantable glucose sensors
Capillary finger-prick blood glucose testing remains the mainstay of self monitoring of blood glucose among people with Type 1 diabetes and the National Institute of Clinical Excellence (NICE) recommend self monitoring of blood glucose up to 7-10 times daily (3) . There are several limitations to this method. Finger-prick testing is nondynamic and only gives a glucose value at a single point in time chosen by the individual. The direction of glucose trend, including impending hypoglycaemia and hyperglycaemia, cannot be detected unless testing takes places within small intervals of time. Barriers to finger-prick testing include the impracticality of testing overnight while asleep, hesitancy to test in certain social settings (such as eating out and while at school/work), and the pain associated with it. Similarly, HbA 1c is used as the gold standard in clinical practice to assess glycaemic control over an average period of approximately 3 months, but again does not give any information on daily fluctuations or variability of blood glucose.
Real-time continuous glucose monitoring technology first reached the market almost two decades ago, and accuracy and usability has improved since then. The use of real-time continuous glucose monitoring overcomes some of the barriers associated with self monitoring of blood glucose and its uptake among people with Type 1 diabetes is increasing (4) .
Real-time continuous glucose monitoring has been shown to improve overall glycaemic control (HbA 1c ) and reduce hypoglycaemia in people with Type 1 diabetes established on pump therapy and multiple daily injections of insulin with suboptimal glycaemic control (5-9). Real-time continuous glucose monitoring also increases the time spent in target glucose range and reduces severe hypoglycaemia (requiring third party assistance to treat) in participants with Type 1 diabetes with impaired awareness of hypoglycaemia, compared with self monitoring of blood glucose (10, 11) , and reduces diabetes-related distress (12) . The use of continuous glucose monitoring during pregnancy was shown to improve both glycaemic and neonatal outcomes (13) . This included a lower incidence of large for gestational age, less neonatal ITU admissions and neonatal hypoglycaemia.
In the UK, the 2015 NICE criteria for real-time continuous glucose monitoring in Type 1 diabetes includes more than one episode of severe hypoglycaemia/year, complete loss of awareness of hypoglycaemia, hypoglycaemia that is causing problems with daily activities, extreme fear of hypoglycaemia, and HbA 1c ≥9% (≥75 mmol/mol) despite testing ≥10 times/day (3) .
Most commercially available real-time continuous glucose monitoring systems such as Dexcom (San Diego, CA, USA) G5 and G6, Medtronic (Northridge, CA, USA) Guardian Connect Sensor 3 and Enlite, and Medtrum (Shanghai, China) S7 Easy Sense, use enzyme-based subcutaneous needle-type sensors that measure interstitial glucose every 5 minutes. This type of subcutaneous sensor can be inserted by the user and needs to be replaced every 7-10 days. All real-time continuous glucose monitoring devices display an estimate of blood glucose, with alerts/alarms for hypoglycaemia and hyperglycaemia and real-time trends in glucose changes. Intermittent glucose monitoring (Abbott, Chicago, IL, USA) Freestyle Libre, also known as flash glucose monitoring, only displays glucose data, including trends when the sensor is scanned with an Near-Field Communication (NFC)-enabled reader or smartphone app (14) . Details of the various subcutaneous needle-based sensors will not be discussed further in this review and the focus will be on implantable sensors.
At present, the only commercially available implantable subcutaneous glucose sensor for real-time continuous glucose monitoring use is the Eversense system (manufactured by Senseonics, MD, USA), which was approved by the Food and Drug Administration and CE-marked in 2017. Eversense comprises a small capsule (the sensor) that is implanted within the subcutaneous tissue of the lateral aspect of the upper arm. Contrary to the glucose oxidase enzyme technology used in the subcutaneous needle-type sensors, the Eversense sensor utilizes optical fluorescence technology and has a sensor life of 180 days (15) . The sensor is surgically inserted under local anaesthetic using an aseptic technique, either by a trained surgeon or physician. Once the sensor is implanted a transmitter is worn externally over the sensor site. The transmitter communicates with the sensor and transmits interstitial glucose data wirelessly via Bluetooth to a receiver (a smartphone-based application) every 5 minutes. The system requires calibration with capillary blood glucose every 12 hours. The mean absolute relative difference has been reported as 8.8% (16) , suggesting better accuracy than the subcutaneous needle-based sensors, which have a reported mean absolute relative difference of 9.0-13.6% (17) (18) (19) .
The main advantages of the implanted Eversense sensor compared with the needle-based subcutaneous sensors are the longer sensor life and better accuracy, but the disadvantages include the invasive nature of sensor insertion requiring clinic attendance. The limitations of the real-time subcutaneous sensor are the sensor lag because of differences between interstitial and blood glucose at any point in time, the need for calibration, and alarm fatigue. Only Dexcom G6 and the Freestyle Libre are calibration-free and licenced for non-adjunctive use for insulin dose-adjustment. Currently, a mean absolute relative difference of <10% is considered to be the level of accuracy required for the safe use of continuous glucose monitoring readings to make insulin-dosing decisions (19) . Intravenous glucose monitoring devices exist, but despite good accuracy, their use in day-to-day diabetes management is limited because of their invasiveness and potential risks.
What's new?
• Implantable devices such as continuous glucose monitoring systems, continuous intraperitoneal insulin infusion pumps and closed-loop insulin delivery systems show great promise in achieving glycaemic control for those with Type 1 diabetes. Awareness that these therapeutic options exist, and their availability, needs to be raised.
• Bariatric or metabolic surgery has been shown to make tremendous improvements to the glycaemic status in people with Type 2 diabetes and obesity. These effects may potentially be translatable to those with Type 1 diabetes and obesity. More systematic and structured premarketing evaluation of continuous glucose monitoring systems performance.
Greater investment in trials to provide evidence for continuous glucose monitoring value and reliability for all patient groups.
Standardization of continuous glucose monitoring data reporting in clinical trials.
Improved consistency and accessibility to safety reports to regulatory authorities for market approval.
Increased communication and cooperation across stakeholder groups.
Continuous intraperitoneal insulin infusion
Continuous intraperitoneal insulin infusion (CIPII) is viewed by some as a valuable alternative to continuous subcutaneous insulin infusion. At the moment it is still mainly used only in cases where there are challenges with the use of continuous subcutaneous insulin infusion. Intraperitoneal insulin is absorbed into the portal system via the visceral peritoneum capillaries. Unlike subcutaneous delivery, insulin is first presented to the liver, promoting hepatic uptake and subsequently reducing the level of insulin within the peripheral circulation. There are several positive effects related to this, including an improved glucose and glucagon response to variable glucose levels and exercise. The effects of intraperitoneal insulin are also faster and support better stability of glucose levels (21, 22) .
There are two types of CIPII delivery system. The first is an entirely implanted programmable pump (Medtronic older MiniMed implantable pump) and the second is an external pump with a percutaneous port that has an intraperitoneal catheter connected (Roche Accu-Chek Diaport System). Implantable pumps have a significantly higher associated cost because of the requirement for follow-up visits. There is a need to refill the insulin reservoir with frequent device removal and to replace the battery at the end of its life. The entirely implantable MiniMed pump is no longer available but the manufacturer still provides consumables for those already using the pump in Europe, but not in the USA. However, the emergence of the newer percutaneous access ports systems such as the Diaport system has refreshed interest in intraperitoneal insulin technology. Table 1 lists some indications and contraindications to CIPII (21) .
Current published data show promising results. A Dutch clinical trial of 23 participants demonstrated that the use of CIPII can improve quality of life and lead to greater patient satisfaction. The same cohort was followed up 6 years later, and glycaemic control was found to be stable. When compared with subcutaneous insulin therapy, there were also fewer hypoglycaemic episodes (23) . A separate study (n=60) conducted by the European Diaport study group showed that CIPII reduced hypoglycaemic episodes and increased quality of life without weight gain (24) . This was echoed by a French systematic review published in 2014 that evaluated 15 publications and which, more importantly, also concluded that CIPII was effective at HbA 1c level reduction and reducing the number of hypoglycaemic episodes (25) . The benefits of CIPII are listed in Table 2 .
As with any device, there are also associated complications (26) . For both types of device, the most common complication is catheter obstruction. Other potential issues include pump dysfunction, port site-or device-associated infection and pain.
In the USA, Food and Drug Administration approval is no longer sought by companies because of issues during the infancy of this technology. Thus, in the USA, individuals with Type 1 diabetes no longer have access to this treatment option unless they travel abroad. Global awareness of this treatment option is low and only a few centres have the expertise to implant and manage CIPII. It is estimated that only 400 patients in total worldwide receive CIPII treatment, with only 50 new individuals considered annually (27) . In the UK, the first Diaport device wasn't implanted until 2015 (28) .
Current data is promising for CIPII. More long-term highquality data is certainly required regarding its effectiveness, long-term complications and metabolic effects. Although the number of individuals who may benefit is relatively low, this cohort is also one with extremely challenging insulin and glucose dynamics on alternative existing regimens of insulin therapy. For those whom continuous subcutaneous insulin infusion is unsuccessful because of a variety of reasons, CIPII provides a potential alternative option to subcutaneous insulin which may improve both glycaemic control and quality of life.
Closed-loop insulin delivery systems
The emergence of subcutaneous continuous glucose monitoring has enabled the development of portable artificial pancreas systems, also referred to as closed-loop insulin delivery systems. An artificial pancreas system comprises a glucose sensor, a control algorithm that calculates the required insulin dose based on dynamic glucose changes, and an insulin pump for insulin delivery. Artificial pancreas systems have been shown to improve glycaemic control and reduce hypoglycaemia over short durations within supervised clinic environments and over longer unsupervised periods at home (29) (30) (31) . Artificial pancreas systems in development utilize either a single hormone (insulin only) or bihormonal (e.g. insulin and glucagon) and are either fully automated or semi-automated (hybrid) systems that require the announcement of certain events such as meals and exercise. The first commercially available hybrid closed-loop system (the MiniMed 670G pump, Medtronic, Northridge, CA, USA) gained Food and Drug Administration approval in 2016 and a CE mark for use in Type 1 diabetes in 2018 (32) .
Most of the artificial pancreas systems in development, including the Medtronic 670G, use a subcutaneous glucose sensor and continuous subcutaneous insulin infusion. In this review we focus our attention on closed-loop insulin systems using CIPII.
An alternative closed-loop insulin delivery system designed to overcome the challenges associated with the pharmacokinetics of insulin delivered in the interstitial space and the subcutaneous sensors, as well as the constraints of wearing an external device, was attempted by Renard et al. in 2006 (n=4) with an implantable system based on intraperitoneal insulin delivery, a proportional integral derivative controller and a venous glucose sensor (33) . The concept was optimistic, and although the results were similar to the subcutaneous closed-loop trials conducted at the same time, the disadvantages associated with the intravenous sensors, such as significant time lag, level of invasiveness and the need for annual replacements, prevented its use in subsequent trials.
In 2010, the same study group conducted another 2-day semi-automatic (pre-meal boluses of insulin given) closedloop trial in 8 participants using a simpler system with a subcutaneous sensor, intraperitoneal insulin delivery and a proportional integral derivative algorithm which showed that a higher percentage of time was spent in the study glucose target (4.4-6.6 mmol/l) during closed-loop vs. openloop (39.1% vs. 27.7%, P=0.05) and 76.5% of the time blood glucose was between 4.4-10 mmol/l in closed-loop vs. 63.7% in open-loop (intraperitoneal insulin) (34) . More recently, a non-randomized 24-hour sequential artificial pancreas study (n=10) comparing a subcutaneous artificial pancreas system (using a fast-acting insulin analogue) with an intraperitoneal artificial pancreas system (using regular insulin via the Diaport system) using a model predictive control algorithm was conducted. The time spent within the primary endpoint glucose target range (80-140 mg/dl) was significantly higher for intraperitoneal delivery than for subcutaneous delivery (39.8AE7.6 vs. 25.6AE13.1, P=0.03) (35) . The first artificial pancreas system integrating the Eversense implantable subcutaneous glucose sensor will be evaluated as part of the International Diabetes Closed Loop (IDCL) trial, but outcome data have not yet been published.
Larger and longer term studies evaluating implantable artificial pancreas systems are required and are underway, but technological advancements may soon set a new breakthrough in the artificial pancreas treatment of Type 1 diabetes (36) . There are still limitations with artificial pancreas systems that need to be addressed, but with improving pump, sensor and artificial intelligence technology, people with Type 1 diabetes will hopefully soon have access to a range of automated artificial pancreas systems to aid self management of their condition. 
Metabolic surgery in Type 1 diabetes
Originally intended for weight loss, metabolic surgery has now been proven to lead to significant Type 2 diabetes resolution and improvement in diabetes-and obesity-related co-morbidities (37, 38) . Globally, 98.8% of operations are performed laparoscopically (39) and were traditionally classified as either restrictive or malabsorptive, or as a combination of the two (Table 3) .
The two most common operations currently performed in the UK are sleeve gastrectomy (Fig. 1) and Roux-en-Y gastric bypass (Fig. 2) (40) . Although the classifications suggest a restrictive and malabsorptive action, the effects of surgery extend beyond this, one description of which includes bile flow alteration, reduction of gastric size, anatomical gut rearrangement and altered flow of nutrients, vagal manipulation and enteric gut hormone modulation (BRAVE) (41) . This collectively contributes to the anti-diabetic postoperative effects. Table 4 illustrates and summarizes some of the recently published long-term clinical trials comparing metabolic surgery with the best medical therapy for Type 2 diabetes remission.
The precise underlying mechanisms have yet to be fully established but there are both weight-dependent and weightindependent factors. There is now growing evidence to suggest that surgery in some people with Type 1 diabetes also has health benefits. It is important to highlight that those with obesity in addition to the symptoms and sequalae unique to Type 1 diabetes are postulated to be the potential benefactors.
Data is currently limited and to date there are no randomized controlled trials published investigating bariatric and metabolic surgery specifically for participants with Type 1 diabetes, but several recently published systematic reviews and meta-analyses demonstrate promising results and potential in this cohort (44, 45) . It is important to note that these cohorts all have Type 1 diabetes and obesity. There is currently very little published literature with results in those with Type 1 diabetes alone.
One meta-analysis published in 2015 found 26 retrospective non-randomized studies. This produced a combined dataset of 142 participants with Type 1 diabetes who underwent bariatric surgery (44) . Postoperatively, pooled analysis of all the studies found that there was a Although fewer studies reported other metabolic measures, systolic and diastolic blood pressure, triglyceride and LDL levels were also shown to decrease. Concurrently, HDL levels increased.
A separate meta-analysis included 9 studies which totalled 78 participants (45) . This meta-analysis reported a minimal change in HbA 1c but a significant reduction in insulin requirements and BMI.
The third and final meta-analysis (46) included a total of 86 participants from 13 studies. Consistent with other studies, there was a significant reduction of HbA 1c from 8.46AE0.78% to 8.13AE0.86%. Mean total daily insulin requirement was reduced from 98 (AE26) units to 42 (AE11) units. A BMI reduction of 12 kg/m 2 was found.
The aforementioned studies have a degree of overlap, but current evidence seems to suggest that people with Type 1 diabetes benefit from a significant reduction in weight and insulin requirements. Glycaemic control also seems to improve but not significantly, and importantly not to the <7% (<53 mmol/mol) level where control is deemed adequate.
A further literature search found four more recent studies not included in the previously discussed meta-analyses showing similar beneficial effects of metabolic surgery in cohorts with Type 1 diabetes ( Table 5) .
Correlation of weight loss and insulin requirement is interesting and challenges the theory that Type 1 diabetes is a condition of purely insulin deficiency. Particularly in those with Type 1 diabetes and concomitant obesity, there may be a degree of overlap between insulin insufficiency and insulin resistance. Improvements in postoperative insulin requirements may be because of improvement in insulin sensitivity, similar to that seen in participants with Type 2 diabetes. Individuals with latent autoimmune diabetes in adults are another subgroup that challenges the overlap of insulin insufficiency and resistance.
The spectrum of disease may also explain why it is sometimes difficult to differentiate between the two. Current use of laboratory tests including C-peptide levels and islet cell antibodies along with clinical correlation can still be extremely challenging (51) .
As we further understand diabetes, the classical Type 1/ Type 2 diabetes classification is increasingly challenged. Type 1 and Type 2 diabetes may belong to different ends of a spectrum driven by an underlying insulin disorder, or perhaps a whole new classification may be required (52) .
In the obese Type 1 diabetes cohort, even if glycaemic control is not drastically improved compared with the cohort with Type 2 diabetes, the improvement in cardiac, metabolic and obesity-associated risk factors such as blood pressure and circulating triglycerides may also be beneficial in the long term, and merits further investigation (53, 54) .
When considering operative intervention, thought needs to be given to the postoperative glucose absorption dynamics, as fluctuations in Type 1 diabetes are much more of a problem compared with Type 2 diabetes. Patients who undergo Roux-en-Y gastric bypass will have more rapid rises and troughs in blood glucose levels compared with sleeve gastrectomy (55) . Sleeve gastrectomy may be more appropriate in Type 1 diabetes because of the more predictable and stable nature of carbohydrate absorption (46, 55) . The safety of those patients undergoing surgery is also another important point that has to be considered. None of the collective studies describe any major complications of note, but those studies were not designed to look at potential complications. Prospective studies and clinical trials are required to further investigate and address this issue.
Type 1 diabetes is a complex multi-system disease process and any patient who undergoes bariatric surgery is at risk of potential complications (56) . Any surgical intervention should be discussed, thoroughly evaluated and managed on a case-by-case basis by a joint bariatric and diabetes multidisciplinary team.
From an academic point of view, metabolic surgery presents a unique opportunity to further understand the underlying mechanisms of the diabetes spectrum. By studying the effects postoperatively, we may gain a different perspective. Through better understanding of underlying pathways, we may subsequently be able to tailor or find new treatment targets to help people with Type 1 diabetes achieve better outcomes. 
Pancreas and islet cell transplantation
The first successful pancreatic transplant was performed in 1966 (57) . Standardization of surgical technique and the progressive introduction of induction T cell-depleting agents and immunosuppressive agents has led to lower rejection rates and improved graft survival rates today (58) . In Type 1 diabetes, whole pancreas transplantation or islet transplantation may be considered as an alternative therapeutic option to intensive insulin therapy in selected individuals. Although transplantation can potentially achieve insulin independence, there are still significant risks associated with surgery and immunosuppression. Whole pancreas and islet transplantation are therefore currently restricted to those already requiring immunosuppression for kidney transplantation or those with unawareness of hypoglycaemia experiencing episodes of life-threatening severe hypoglycaemia.
Individuals with Type 1 diabetes considered for pancreas or islet transplantation broadly fall into three categories: (i) simultaneous pancreas kidney or simultaneous islet kidney transplants are performed in those with chronic kidney disease (calculated GFR ≤20 ml/min); (ii) pancreas or islet after kidney transplants are performed in those with a previous kidney transplant who have maintained satisfactory renal function (those considered for islet after kidney transplants must also have a history of severe hypoglycaemia or a HbA 1c >53 mmol/mol); and (iii) pancreas transplant alone or islet alone are performed in those with normal or near-normal renal function and disabling hypoglycaemia (evidenced by episodes of severe hypoglycaemia and significant impaired awareness of hypoglycaemia) (59) . When compared with simultaneous pancreas kidney transplants, pancreas transplants alone have a higher rate of technical graft loss (58) . Pancreas transplant alone remains controversial because although recipients report an improved quality of life, improved patient survival has yet to be demonstrated. Pancreas transplant alone is also an independent risk factor for developing renal failure in those who would otherwise have normal or near-normal renal function (60) . This explains why there is a relatively lower number of pancreas transplants alone performed.
The latest UK annual report on pancreas and islet transplantation (61) showed graft survival rates (mean 95% confidence interval) of 89 (86-91)% and 79 (75-82)% at 1 year and at 5 years after simultaneous pancreas and kidney transplant, respectively. Graft survival for pancreas transplants alone are 88 (77-94)% and 52 (42-61)% at 1 year and at 5 years, respectively. The 1-year graft survival of a routine islet transplant is 84 (73-91)%. For those recipients with a functioning graft at 1-year post-transplant, the 5-year graft survival is 60 (42-74)% for those recipients who receive an additional priority islet graft and 44 (24-62)% for those who don't. Balancing the potential risks and benefits of pancreas and islet transplantation requires a Table 5 Recent published studies found outside the systematic reviews discussed demonstrating the effects of metabolic surgery on HbA comprehensive clinical evaluation in a specialist transplant unit.
Conclusion
Management of Type 1 diabetes, despite the best efforts of the person with Type 1 diabetes and their healthcare professional, can be challenging and frustrating. However, the surgical and technological advances detailed in this review provide a whole new world of possibilities in treatment pathways. Implantable continuous glucose sensors, continuous intraperitoneal insulin infusion pumps, closed-loop insulin delivery systems and metabolic surgery all show good promise. Each approach comes with its own advantages and disadvantages. Any diabetes management strategy involving surgical intervention should ideally be discussed in a joint diabetes multidisciplinary team setting. The best treatment approach will depend on the individual's specific indications. There is no doubt that more long-term clinical studies are required for all of the surgical interventions listed, but awareness that these options exist, and their availability, needs to be raised.
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